Single answer
Is Actuate Therapeutics Inc (ACTU) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
Decision snapshot
Everything you need to act fast, in one glance.
What is the conclusion?
Right now our advanced algorithms say:
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Actuate Therapeutics Inc is $21.00, which is $16.94 (417.24%) above the current price today's price.
Low target: $21.00 | High target: $21.00
Company snapshot
A quick overview of the business and its public profile.
Actuate Therapeutics Inc a clinicalstage biopharmaceutical company focuses on developing therapies for the treatment of cancers The companys lead product candidate is Elraglusib Injection a novel glycogen synthase kinase3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma It also develops Elraglusib for the treatment of Ewing sarcoma metastatic melanoma and colorectal cancer The company was formerly known as Apotheca Therapeutics Inc and changed its name to Actuate Therapeutics Inc in October 2015 The company was incorporated in 2015 and is based in Fort Worth Texas
Website: https://actuatetherapeutics.com
Rates and inflation backdrop
US inflation for January 2026 was 0.17%. Over the last 12 months, inflation is 2.83%. The 10-year yield is 4.04 and is down -0.110 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.00. Cash flow to debt ratio: 0.00. Net profit margin: 0.00%. Inflation risk score: medium (0.60/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
No, the average daily trading liquidity for Actuate Therapeutics Inc is $453,183. Trading in stocks with this little trading liquidity is very dangerous, and you can get into a situation where it will be hard to trade your stocks. In addition, these types of stocks usually have very high volatility.
10-year return check
We cannot find data for Actuate Therapeutics Inc 10 years ago, but if you had invested on 2025-01-08 when the price was $8.00, you would have made a loss of $3.94 per share or 49.25%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.